Recent changes
GovPing tracks 141 sources for this role out of 2,348 total sources on GovPing, covering Guidance, Enforcement, Rule, Notice, and Consultation instruments. There were 722 changes in the last 7 days.
Health Canada issued a Type I recall for nitrous oxide chargers sold by DOODELZ, Gold Whip, and Whip-it! brands without market authorization, while the UK VMD called for a Class II recall of Zoetis's Scabigard Suspension for cutaneous administration. FDA classified Draeger's Atlan A350 anesthesia workstations as a Class I recall due to potential piston ventilator failure, and Morovan recalled approximately 4,000 units of Gel Nail Polish Remover for methylene chloride and chloroform contamination.
Fungal Spore Production Method Using Dual Liquid Medium
The USPTO published patent application US20260098242A1 covering a method for producing fungal spores using a dual liquid medium system. The first medium has a lower carbon content than the second medium. Inventors: Van De Zilver Eric, Laurens Van Leeuwen. Application filed September 26, 2023; published April 9, 2026.
Mammoth Biosciences CRISPR Dystrophin Editing Patent Application
USPTO published patent application US20260097134A1 assigned to Mammoth Biosciences, Inc. covering CRISPR-Cas systems and methods for editing human dystrophin genes to treat Duchenne muscular dystrophy (DMD). The application includes compact Type V CRISPR-associated proteins, RNA-dependent DNA polymerase, and guide nucleic acids for gene modification therapies.
Recombinant AAV Vectors for Treating Muscular Dystrophy
USPTO published patent application US20260097132A1 assigned to Sarepta Therapeutics, Inc. covering recombinant adeno-associated virus (rAAV) vectors for expressing human micro-dystrophin gene to treat muscular dystrophy, including Duchenne Muscular Dystrophy. The application includes methods for genotyping DMD gene to determine rAAV gene therapy contraindications. Filing date was September 22, 2023.
T Cell Function Modulation Using CRISPR-Cas Epigenetic Systems
T Cell Function Modulation Using CRISPR-Cas Epigenetic Systems
Advagene Biopharma Patent for Asthma Treatment Using Detoxified E. coli Labile Toxin
USPTO published patent application US20260098065A1 assigned to Advagene Biopharma Co., Ltd. covering methods for treating eosinophil-driven inflammation including severe asthma using a composition for mucosal administration comprising detoxified Escherichia coli labile toxin.
LANMODULIN ORTHOLOGS WITH IMPROVED RARE EARTH SEPARATION PERFORMANCE
USPTO published patent application US20260098064A1 for lanmodulin orthologs (proteins) designed to bind rare earth metals with enhanced REE/REE selectivity. The application covers proteins with four EF hand motifs, methods of using the proteins, and devices/kits containing them. The invention has applications in rare earth element separation and processing.
HPV Vaccine Peptide Constructs with Ligand-Inducible Gene Switch Systems
The USPTO published patent application US20260098063A1 titled 'Human Papillomavirus Vaccines and Uses of the Same.' The application covers engineered HPV molecular vaccine constructs incorporating ligand-inducible engineered gene switch systems for modulating expression of heterologous genes, such as cytokines, in host cells. The application was filed on July 7, 2025, by inventors including Douglas E. Brough and Cheryl G. Bolinger. Patent applications are published for informational purposes and do not grant enforceable rights until issued as a patent after examination.
Lipid Particles Comprising Variant Paramyxovirus Attachment Glycoproteins
USPTO published patent application US20260098062A1 assigned to Sana Biotechnology, Inc. covering lipid particles comprising variant Paramyxovirus attachment glycoproteins with reduced glycosylation and methods for their production and use. The application (originally filed September 21, 2023) covers viral-based particles with modified G/H proteins and their therapeutic applications.
EphA2-binding Peptide and Composition Patent Application
The USPTO published patent application US20260098061A1 for an EphA2-binding peptide and composition comprising such peptides. The application, filed on September 28, 2023, lists 13 inventors including Takanori Aoki and others. The patent covers peptides that bind to the Eph receptor A2 (EphA2) and compositions containing such peptides, with CPC classifications C07K 7/64 and A61K 47/64.
Macrocyclic CFTR Modulators for Cystic Fibrosis
USPTO published patent application US20260098060A1 for macrocyclic CFTR modulators for treating cystic fibrosis. The application covers compounds of Formula (I), their preparation, pharmaceutical salts, and uses as CFTR modulators or in combination with CFTR potentiators/correctors. Inventors include Martin Bolli, Christine Brotschi, John Gatfield, and others. The application was filed on September 14, 2023.
Get daily alerts for pharma & life sciences
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
735 changes in last 7 days
Latest high priority updates
142 official sources tracked
Frequently asked questions
What does this feed cover?
FDA warning letters, novel drug approvals, drug shortage notices, ICH guideline updates, USP notices, EMA news, DEA scheduling decisions, and TGA/WHO standards.
Who is this for?
Regulatory affairs professionals, pharmacovigilance teams, and medical affairs groups at pharma companies and CROs who need to track FDA and EMA actions.
How often is this updated?
GovPing checks source pages multiple times daily. FDA warning letters and drug approvals typically appear within hours of publication.
Does this cover EMA and international regulators?
Yes. We monitor the EMA, ICH, WHO, TGA (Australia), and other international health authorities alongside FDA.
How is this different from AgencyIQ?
AgencyIQ is a full FDA intelligence platform. GovPing is a free feed of the FDA, EMA, and ICH source pages where warning letters, approvals, drug shortages, and guidance are first published - AI-summarized with attention-level ratings on every change.
Is GovPing free?
Yes. GovPing is free, and always will be. We believe government regulatory data should be accessible to everyone. For custom monitoring of pages we don't cover yet, Changeflow starts at $99/mo.
Need to monitor something else?
GovPing covers the common sources. For niche pages specific to your team, add custom URL monitoring with Changeflow.
Get Pharma & Life Sciences alerts
Daily digest of pharma & life sciences regulatory changes. AI-summarized, no noise.
Free. Unsubscribe anytime.